The risk that establishing the manufacturing, transportation, sales and supply-chain infrastructure required for the clinical trials, supply and sale of pharmaceuticals and related products may prove difficult or be delayed, resulting in supply delays and an impact on business plans. This also includes regulatory findings concerning data and management systems.